Pulse Medical receives FDA Breakthrough Device Designation for its μFR® system
SHANGHAI, May 26, 2023 /PRNewswire/ -- Pulse Medical Technology, Inc. (Pulse Medical) 4th generation μFR® system has received an FDA Breakthrough Device designation. Pulse Medical, founded in 2015, located in Shanghai, China, is dedicated to developing innovative technology for precise diagnosis and optimal treatment of patients with pan-vascular disease. Pulse Medical has been pioneering and invented the key...
Members Health Calls for National Reform to Strengthen Healthcare and Bolster Economic Prosperity and Social Wellbeing
MELBOURNE, Australia, Oct. 16, 2024 /PRNewswire/ -- Members Health is calling for major reforms to boost health care accessibility and affordability and improve transparency of hospitals and doctors across Australia as part of a landmark report released today for the not-for-profit health insurance sector. The 'Economic and Social Impact of the Members...
EVERSANA unveils global price and market access solution NAVLIN by EVERSANA
Next generation price and market access platform combining data, software and insights into single ecosystem CHICAGO, March 17, 2022 /PRNewswire/ -- EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, today unveiled NAVLIN by EVERSANA™, a new, comprehensive ecosystem of price and access solutions to help established...
Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, July 12, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, announced today that the Group has completed IND-enabling studies for STP125G, an siRNA therapeutics targeting Apolipoprotein C3 (ApoC3), based on its proprietary GalAhead™ mxRNA technology....
Shanton Screens First Subjects in Phase 2b Refractory/Tophaceous Gout Study with SAP-001
SAP-001 is an oral once-a-day investigational gout product with Best-in-Class potential for acute and chronic use in uncontrolled patients BRIDGEWATER, N.J., Jan. 9, 2023 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a groundbreaking treatment for refractory and tophaceous gout patients, today announced the initiation of its RID GOUT Study, a Phase 2b study for Shanton's investigational drug...
Asieris Releases 2022 Annual Report: Makes Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions
SHANGHAI, April 17, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma company specializing in the discovery, development and commercialization of innovative drugs that treat genitourinary (GU) tumors and other related diseases, today released its 2022 annual report. While enhancing its product pipeline with steady progress in its global clinical trials, Asieris is building up its core marketing and sales...
The Grand Opening of HKSH’s Proton Therapy Centre Marks a Significant Advancement in Precision Cancer Treatment in Hong Kong
HONG KONG, Dec. 2, 2023 /PRNewswire/ -- HKSH Medical Group (HKSH) announced today the grand opening of the HKSH Proton Therapy Centre (the Centre) – the first of its kind in Hong Kong. Located at the HKSH Eastern Medical Centre in A Kung Ngam, Shau Kei Wan, the Centre boasts two state-of-the-art treatment rooms and a cutting-edge proton therapy...
EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH
Establishment of Joint Venture Company named SanPlena in the US Drug-device combination of EOFlow's smart wearable drug delivery platform and novel peptide derivatives developed by a team led by Prof. Sir Stephen Bloom, world-renowned researcher in the field of obesity and metabolism at Imperial College London (UK) 10-15% weight loss in 2-3 months eyed with...
R&D Milestone: HebaBiz Biotech’s application for phase III clinical trial in China for Clevudine (L-FMAU), an anti-hepatitis B virus drug candidate under development has been approved
BEIJING, Nov. 15, 2021 /PRNewswire/ -- HebaBiz Biotech is pleased to announce that in November 2021, the Center for Drug Evaluation (CDE) of The National Medical Products Administration (NMPA) of China has approved the application for phase III clinical study of Clevudine (L-FMAU), a drug candidate under development for chronic hepatitis B virus (HBV), the application of which was...
AnPac Bio-Medical Science Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting the Equity Rule on or before July 12, 2023
NEW YORK, March 23, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced that on March...
